Physician profile
John E Anderson
NPI 1003801788
$1,471,225.84
in general payments reported to CMS, 2019-2025
49 companies · $158K in 2025
The $158K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $334K · 2020: $240K · 2021: $243K · 2022: $195K · 2023: $146K · 2024: $155K · 2025: $158K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $322K · Consulting Fee: $77K · Travel and Lodging: $29K · Food and Beverage: $17K · Honoraria: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,900 · Long Term Medical Supply Or Device Loan: $29.97 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $322,358.62 |
| Consulting Fee | $77,032.35 |
| Travel and Lodging | $29,161.87 |
| Food and Beverage | $16,698.28 |
| Honoraria | $11,993.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,900.00 |
| Long Term Medical Supply Or Device Loan | $29.97 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $574,142.95 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $236,155.51 | 2019-2025 | |
| Novo Nordisk INC | $226,309.70 | 2019-2025 | Ozempic, Rybelsus, Victoza |
| Astrazeneca Pharmaceuticals Lp | $135,949.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Eli Lilly and Company | $75,962.93 | 2019-2025 | Jardiance, Mounjaro |
| Corcept Therapeutics | $42,734.45 | 2023-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $37,918.16 | 2020-2024 | |
| Abbott Laboratories | $37,720.47 | 2019-2025 | Freestyle Libre 3, Afinion 2, Freestyle Insulinx |
| Janssen Pharmaceuticals, INC | $37,653.27 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18,647.83 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Alfasigma USA, INC. | $11,792.50 | 2020-2021 | |
| Regeneron Pharmaceuticals, INC. | $9,614.70 | 2024 | |
| Insulet Corporation | $6,095.20 | 2021-2025 | Omnipod |
| Novartis Pharmaceuticals Corporation | $4,372.69 | 2019-2022 | |
| Astellas Pharma US INC | $3,128.56 | 2019-2025 | Veozah, Myrbetriq |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Ab | $2,685.00 | 2022 | |
| Sanofi Pasteur INC. | $2,670.00 | 2021 | |
| Astrazeneca Uk Limited | $1,611.00 | 2023 | |
| Pfizer INC. | $1,396.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,140.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $613.51 | 2020-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $471.58 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $462.59 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $194.21 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $188.39 | 2019-2025 | Capvaxive, Verquvo |
| Exact Sciences Corporation | $156.89 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $153.47 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $143.91 | 2023-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $129.74 | 2024-2025 | Zenpep |
| Allergan, INC. | $101.88 | 2019-2020 | |
| Dexcom, INC. | $98.95 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $94.24 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $93.01 | 2022 | |
| Mannkind Corporation | $89.57 | 2019-2023 | Afrezza |
| Medtronic, INC. | $89.31 | 2024 | Minimed 780g |
| Biohaven Pharmaceuticals, INC. | $78.40 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $59.39 | 2019-2024 | |
| Inspire Medical Systems, INC. | $44.13 | 2024 | Inspire |
| Sumitomo Pharma America, INC. | $40.82 | 2023-2025 | Gemtesa |
| Daiichi Sankyo INC. | $32.88 | 2019-2024 | Injectafer |
| Cequr Corporation | $29.50 | 2025 | Cequr Simplicity |
| Shield Therapeutics INC | $29.38 | 2024 | |
| Neuronetics, INC. | $25.83 | 2019 | |
| Nestle Healthcare Nutrition INC. | $20.88 | 2021 | |
| Esperion Therapeutics, INC. | $20.79 | 2021 | |
| Hologic Sales and Service, LLC | $19.98 | 2019 | |
| Philips North America LLC | $18.23 | 2024 | (Ck7) Extended Holter |
| Amarin Pharma, INC. | $12.96 | 2019 | |
| Redhill Biopharma INC. | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,357.24 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.